Skip to main content

Table 1 Patient characteristics

From: Dual time point 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer

Parameter Number of cases(%)
Total 464(100.0)
Age (year)Mean ± SD (range)61.4 ± 12.6(28–91)
 <  45113(23.4)
≥ 45351(75.6)
Tumor invasive size (mm)Mean ± SD (range)20.6 ± 17.6(0.0–150.0)
 ≤ 20297(64.0)
>  20167(36.0)
Pathological T factorpTis14(3.0)
pT1283(61.0)
pT2144(31.0)
pT323(5.0)
Histological typeDuctal carcinoma in situ14(3.0)
Invasive ductal carcinoma366(78.9)
Special type84(18.1)
Nuclear grade1156(33.6)
2128(27.6)
3180(38.8)
Lymphatic invasionNegative271(58.4)
Positive193(41.6)
Pathological N factorpN0334(72.0)
pN195(20.5)
pN226(5.6)
pN39(1.9)
Estrogen receptorNegative83(17.9)
Positive381(82.1)
Progesterone receptorNegative120(25.9)
Positive344(74.1)
HER2Negative401(86.4)
Positive50(10.8)
Not done13(2.8)
Ki-67 labeling index (%)Mean ± SD (range)19.8 ± 16.6(0–90.0)
 <  14192(41.4)
≥ 14239(51.5)
Not done33(7.1)
SubtypeER-positive/HER2-negative345(74.3)
ER-positive/HER-positive26(5.6)
ER-negative/HER2-positive24(5.2)
ER-negative/HER2-negative56(12.1)
Not done13(2.8)
Pathological stage013(2.8)
I236(50.8)
II172(37.1)
III43(9.3)
SUVmax1Mean ± SD (range)4.6 ± 3.5(0.7–24.2)
SUVmax2Mean ± SD (range)5.6 ± 4.9(0.9–36.4)
ΔSUVmax%Mean ± SD (range)15.6 ± 20.2(−36.7–84.2)
Relapse-free survival rate (%)5-year92.0 
10-year84.9 
Overall survival rate (%)5-year97.3 
10-year88.5 
  1. HER2, human epidermal growth factor receptor 2
  2. SD, standard deviation
  3. SUV, standardized uptake value